Samsung Biologics, the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins.

Under the terms of the agreement, South Korea based Samsung Biologics will provide its end-to-end cell line development and clinical drug substance and drug product manufacturing services as well as IND filling support for KAHR's drug candidate DSP502, a TIGITxPD1 fusion protein.

As an innovative leader in the fusion protein space, KAHR's current technology is based on multi-functional immuno-recruitment proteins (MIRP) that bind cancer cells and T-cells to produce a synergistic effect to selectively target tumors.

KAHR recently signed an exclusive license with Thomas Jefferson University in Philadelphia, PA to develop and commercialize multiple new drug candidates, including DSP502.

John Rim, CEO of Samsung Biologics said, "We will leverage our fully integrated, scalable, and high-quality development services and experienced teams to enable a faster transition from gene to IND in order to ensure KAHR's success in bringing cutting edge immuno-recruitment cancer drugs to patients in need."